Bayer Corporation’s Projects have won the “Platinum Ounce” open competition between professionals in the pharmaceutical industry. The company was a winner in several categories, including “Dynamics of the Year” with their promotion campaign for the “Klayra” drug, and “Launch of the Year” with their promotional campaign for the “Visanna” drug.
“Platinum Ounce” is traditionally considered to be the main event of the pharmaceutical industry and annually attracts the attention of the major players in the market. The entries in 2013 were evaluated by 80 leading industry experts – scientists, representatives of the business community and the relevant universities. This year there were a record number of applications submitted for the categories “Launch of the Year” and “Project of the Year”.
Bayer is a leading international company which specializes in public health services, plant protection and hi-tech materials. As an innovative company, Bayer sets trends in research-intensive areas. The company’s products and services are designed to benefit people and improve their quality of life. “Visanna” is a modern and effective drug created by Bayer specifically to deal with endometriosis. “Qlaira” is a next generation combined oral contraceptive containing estrogen identical to that found in nature. It has a minimal effect on the body and acts in harmony with a woman’s nature.
PR support of Bayer in Russia is provided by FleishmanHillard Vanguard.
«Bayer»: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovative company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal 2012, the Group employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2.0 billion, R&D expenses to €3.0 billion. For more information, go to www.bayer.com.